Headquartered in 1 Francis Crick Avenue, Cambridge·Fiscal year ends December·NASDAQ: AZN·astrazeneca.com
About AstraZeneca
AstraZeneca PLC is a global biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of prescription medicines across four main therapy areas: Oncology, Cardiovascular/Renal/Metabolism (CVRM), Respiratory & Immunology (R&I), and Rare Disease, with additional operations in Infectious Disease (Vaccines & Immune Therapies). The company's portfolio includes blockbuster oncology drugs such as Tagrisso (EGFR-mutant lung cancer), Imfinzi (immuno-oncology across lung, liver, bladder, and GI cancers), Lynparza (PARP inhibitor for breast and prostate cancers), Enhertu (HER2-targeted antibody-drug conjugate, partnered with Daiichi Sankyo), and Calquence (BTK inhibitor for blood cancers). In CVRM, Farxiga is a major SGLT2 inhibitor for diabetes, heart failure, and chronic kidney disease, though now facing generic competition. The Rare Disease unit, built on the Alexion acquisition, markets Ultomiris and Soliris for complement-mediated diseases and Strensiq for hypophosphatasia. AstraZeneca partners extensively with companies including Daiichi Sankyo (Enhertu, Datroway), Amgen (Tezspire), Sanofi (Beyfortus), and Merck (Lynparza). The company operates globally with significant revenue contributions from the United States (43%), Europe (22%), and Emerging Markets including China (27%). AstraZeneca is pursuing a target of $80 billion in Total Revenue by 2030, driven by new product launches, indication expansions, and a deep late-stage pipeline with more than 20 high-value readouts expected over the next 18 months. Updated
Latest Activity
PodcastMad Money w/ Jim CramerJim Cramer · 44 min
Mad Money w/ Jim Cramer 10/27/26
Cramer rejects the AI all-clear despite Broadcom arranging $63 billion in financing for Anthropic compute
Meta's $25 billion equity raise was five times oversubscribed, but the $60 billion at-the-market program worries him
CoreWeave bonds reaching a 15% yield flagged as the sector's unresolved weak spot
Caller questions on Micron volatility and Revolution Medicines' pancreatic cancer drug
The bull case for data centers today rested on financing rather than profits, and Cramer wants to hear a customer say the chips are minting money before calling it clear. He expects Meta's at-the-market selling to weigh on the stock as supply hits at the wrong moments, with borrowing costs into a Fed decision the swing factor for everything levered to the buildout.
A 53% cut in death risk versus chemotherapy is the kind of late-stage result that resets an oncology franchise, and it lands after a stretch of pipeline setbacks weighed on the shares. Watch for the full trial data and filing timeline.
BREAKING: AstraZeneca reports major breakthrough in stomach cancer treatment, with its experimental drug reducing the risk of death by 53% compared with chemotherapy in a late-stage trial.
The downside is doing the damage at Wednesday's open: Applied Optoelectronics is off 10.13%, with Dell and SanDisk each shedding roughly 9%. The best gainer, Intuit at 5.07%, does not come close to matching it.
AstraZeneca (NYSE:AZN | AZN Price Prediction) reports third-quarter results on Friday, October 30. Farxiga generics are cutting into sales, and a major cardiology trial has failed. This report shows whether oncology and…
Roughly 700,000 seniors have started GLP-1 obesity treatments since Medicare’s Bridge program launched July 1, 2026, according to Eli Lilly (NYSE:LLY | LLY Price Prediction) CEO David Ricks. Eligible beneficiaries pay $50…
AstraZeneca just locked in a price to own 12% of Summit Therapeutics that the open market refuses to match, and two clinical deadlines in 2026 will determine whether Wall Street or the…
Novartis just handed the entire Lp(a) drug class a failing grade, and Amgen is taking the worst of the punishment despite releasing promising trial results of its own on the very same…
Wall Street analysts reshuffled the deck on Monday with a wave of upgrades, downgrades, and fresh initiations spanning pharma giants, fast-casual chains, and streaming players. Find out which names got bullish bets…
Kailera Therapeutics raised one of the biggest obesity biotech IPOs in recent memory, then watched its stock drop nearly 30%. Now several of the world's largest drugmakers have a compelling reason to…
BioCryst just turned profitable, its HAE drug Orladeyo is minting cash, and a rival's blockbuster acquisition just put the whole rare-disease sector in play. So which pharma giant has the most to…
Geopolitical relief triggered a sharp selloff in oil and a Treasury retreat, handing bulls an opening to reclaim momentum at the start of August, but a surprise move from MicroStrategy and a…
The FDA just approved the first once-daily oral PCSK9 pill, and five major stocks now sit in the crosshairs. Not all of them come out ahead, and the biggest surprise winner may…
Eli Lilly (NYSE:LLY | LLY Price Prediction) is finally acting like a trillion-dollar drugmaker again. After a brutal stretch in late 2025 and a wobbly start to this year, the stock punched…
Franklin FTSE International Low Volatility High Dividend Index ETF (NYSEARCA:LVHI) closed Friday at $41 after a quarterly distribution cycle that continues to deliver the income international dividend investors buy this fund for.…
The iShares Core MSCI EAFE ETF (NYSEARCA:IEFA) has quietly become one of the year’s standout core holdings, trading near $97 after a 8% year-to-date run and a 22% one-year gain. With $169.6…
Dividend income arrives whether markets rally or sell off. For investors seeking recurring cash flow, high-yield equities remain the cleanest source outside a paycheck. They settle in cash, clear immediately, and can…
Our AstraZeneca (NASDAQ:AZN | AZN Price Prediction) call comes one day after the British drugmaker reported Q1 2026 revenue of $15.29 billion, up 13% year over year, and reaffirmed full-year guidance. With…
AstraZeneca PLC is a global biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of prescription medicines across four main therapy areas: Oncology, Cardiovascular/Renal/Metabolism (CVRM), Respiratory & Immunology (R&I), and Rare Disease, with additional operations in…
What is the AZN stock price target?
24/7 Wall St.'s 12-month price target for AZN is $214.86, rated Buy. The Wall Street consensus target is $206.66. AZN price prediction →